Role Of PD-1 Immune Checkpoint Inhibition in Lung Cancer Treatment
DOI:
https://doi.org/10.54097/4xtxrx26Keywords:
NSCLC; PD-1; PD-L1; immunotherapy.Abstract
Non-small cell lung cancer (NSCLC) can be distinguished by histopathology and tumor markers. The treatment methods of NSCLC mainly include radiotherapy, chemotherapy, surgical treatment and TCM therapy. PD-1/PD-L1 immunotherapy has an advantage in combination therapy, producing a low-toxic, long-acting antitumor immune response in cancer therapy. This thesis describes the main methods of NSCLC therapy, details the PD-1/PD-L1 pathway and immunotherapy, and studies applications of three monoclonal antibodies in monotherapy and combination therapy. We conclude that the combination therapy has the outstanding advantage of safety, mild effect and prediction, but the problem of drug resistance to PD-1/PD-L1 needs to be solved urgently.
Downloads
References
Vyse S, Huang PH. Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. Expert Rev Anticancer Ther. 2022;22(1):3-16.
Johnson ML, Cho BC, Luft A, et al. Durvalumab with or Without Tremelimumab in Combination with Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol. 2023;41(6):1213-1227.
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current research in cancer. Am J Cancer Res. 2020;10(3):727-742. Published 2020 Mar 1.
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028.
Garris CS, Arlauckas SP, Kohler RH, et al. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. Immunity. 2018;49(6):1148-1161.e7.
Gao J, Shi LZ, Zhao H, et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167(2):397-404.e9.
Horn L, Spigel DR, Vokes EE, et al. Nivolumab Versus Docetaxel in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924-3933.
Reck M, Schenker M, Lee KH, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes result from the randomised, open-label, phase III CheckMate 227 trial. Eur J Cancer. 2019;116:137-147.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833.
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078-2092.
Yang JJ, Huang C, Fan Y, et al. Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study. Cancer Immunol Immunother. 2022;71(6):1393-1402.
Ren S, Chen J, Xu X, et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. J Thorac Oncol. 2022;17(4):544-557.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
